Reply to Cobussen et al: Gentamicin in Patients With Severe Sepsis and Septic Shock in the ICU: A Benefit or a Burden? Reply

Ong, David S Y; Bonten, Marc J M; Cremer, Olaf L

doi:https://doi.org/10.1093/cid/cix448

Reply to Cobussen et al: Gentamicin in Patients With Severe Sepsis and Septic Shock in the ICU: A Benefit or a Burden? Reply

DSpace/Manakin Repository

Reply to Cobussen et al: Gentamicin in Patients With Severe Sepsis and Septic Shock in the ICU: A Benefit or a Burden? Reply

Ong, David S Y; Bonten, Marc J M; Cremer, Olaf L

(2017) Clinical Infectious Diseases, volume 65, issue 5, pp.

(Comment)

Download/Full Text

The full text of this publication is not available.

Version on publisher website for UU-students and staff

Version on publisher website

Keywords: Cohort Studies, Gentamicins, Humans, Prospective Studies, Sepsis, Shock, Septic, Letter, Research Support, Non-U.S. Gov't, Comment

DOI: https://doi.org/10.1093/cid/cix448

ISSN: 1058-4838

Publisher: Oxford University Press

Note: Funding Information: ed by the Center for Translational Molecular Medicine (institutional grant support to D. S. Y. O. and O. L. C.). Potential conflicts of interest. All authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

(Peer reviewed)